Cross-source evidence timeline

Sermorelin research timeline

Follow 6 selected, directly cited source records from December 28, 1990 through October 20, 2021. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

6Selected records
6Source years
2Evidence lanes
October 20, 2021Latest source date

Source year

2021

1 record
  1. Literature metadata

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?↗

    PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

1 record
  1. Literature metadata

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.↗

    PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2013

1 record
  1. Regulatory

    Federal Register notice 2013-04827↗

    The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.↗

Source year

2009

1 record
  1. Regulatory

    Federal Register notice E9-11628↗

    The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin.↗

Source year

1997

1 record
  1. Regulatory

    Drugs@FDA application NDA020443↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients.↗

Source year

1990

1 record
  1. Regulatory

    Drugs@FDA application NDA019863↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients.↗